Johnson & Johnson (JNJ) Position Trimmed by Nationwide Fund Advisors

Nationwide Fund Advisors decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,488,975 shares of the company’s stock after selling 6,508 shares during the quarter. Johnson & Johnson comprises approximately 0.8% of Nationwide Fund Advisors’ holdings, making the stock its 8th largest position. Nationwide Fund Advisors owned about 0.06% of Johnson & Johnson worth $193,582,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in JNJ. State Street Corp raised its holdings in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after acquiring an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after buying an additional 2,581,562 shares in the last quarter. Hedge funds and other institutional investors own 65.70% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) opened at $139.72 on Monday. The company has a market capitalization of $375,360.59, a price-to-earnings ratio of 24.26, a price-to-earnings-growth ratio of 2.84 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period last year, the company earned $1.68 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a $0.84 dividend. The ex-dividend date was Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

A number of equities analysts have recently issued reports on JNJ shares. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Citigroup started coverage on Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price for the company. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Finally, UBS Group reissued a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Saturday, September 30th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $145.52.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/01/johnson-johnson-jnj-position-trimmed-by-nationwide-fund-advisors.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply